The rising prevalence of diseases affecting the pleura such as lung cancer, tuberculosis, mesothelioma and others is a key driver propelling the growth of the market. It is estimated that 2.8 million new cases of lung cancer occurred globally in 2020 according to WHO. Further, increasing adoption of minimally invasive procedures for pleural disease diagnosis and treatment is also fueling the market growth. Pleural biopsy using minimally invasive techniques such as thoracoscopy provides more accurate diagnosis compared to conventional blind pleural biopsy techniques with higher sample adequacy.
Request for a sample of this research report @ https://www.coherentmarketinsights.com/insight/request-sample/6038
Key Market Trends:
Rising preference for image-guided pleural procedures and product innovations are the major trends witnessed in the pleural diseases market. Image-guided pleural procedures such as ultrasound-guided and CT-guided pleural procedures are gaining increasing acceptance among healthcare professionals due to advantages such as real-time visualization, accuracy and safety. Further, key players are focused on developing innovative products to expand their product portfolio and market share. For instance, B. Braun Medical Inc. provides ultrasound-guided pigtail catheters such as SonoPleural for image-guided drainage of pleural effusions.
Pleural Diseases Market Report Coverage
|
Report Coverage |
Details |
|
Market Revenue in 2023 |
US$ 5.01 billion |
|
Estimated Value by 2030 |
US$ 8.13 billion |
|
Growth Rate |
Poised to grow at a CAGR of 7.2% |
|
Historical Data |
2018–2022 |
|
Forecast Period |
2023–2030 |
|
Forecast Units |
Value (USD Million/Billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
By Disease Type, By Diagnostic Tools, By Treatment Modalities, By End User |
|
Geographies Covered |
North America, Europe, Asia Pacific, and Rest of World |
|
Growth Drivers |
Increasing Prevalence of Respiratory Diseases Technological Advancements in Diagnostic Tools and Imaging Focus on Personalized Medicine Increasing Investments in Research and Development |
|
Restraints & Challenges |
Limited Awareness and Delayed Diagnosis Cost of Diagnostic Tools and Treatment Limited Availability of Expertise and Resources |
Market Opportunities
The pleural diseases market by diseases type is segmented into malignant and non-malignant diseases. The non-malignant diseases segment held the largest market share in 2019 and is expected to grow at a CAGR of 6.8% during the forecast period. Non-malignant pleural diseases are more common than malignant pleural diseases. Conditions like pleurisy, pneumothorax, and pleural effusion account for the large market share of this segment. Advancements in treatment options for conditions like recurrent pneumothorax have also contributed to the growth of this segment.
The diagnostic tools segment of the pleural diseases market is segmented into thoracentesis, biopsy, imaging tests, and others. The imaging tests segment held the largest market share in 2019 and is expected to exhibit the highest CAGR over the forecast period. Advancements in imaging modalities like CT scans, ultrasound, MRI, and PET scans have improved the diagnosis of pleural diseases. CT scans are considered the gold standard for diagnosing pleural diseases and monitoring treatment response. Wide acceptance and availability of imaging tests are driving the growth of this segment.
Immediate Delivery is Available | Get Full Report Access@ https://www.coherentmarketinsights.com/insight/buy-now/6038
Key Market Takeaways
The global pleural diseases market size was valued at USD 5.1 Billion in 2024 and is expected to witness a CAGR of 7.2% during the forecast period. Increasing incidence of lung cancers and prevalence of other pleural conditions are anticipated to drive market growth. Based on diseases type, the non-malignant diseases segment dominated the market in 2024 due to the higher occurrence of conditions like pneumothorax and pleural effusion.
By diagnostic tools, the imaging tests segment is expected to hold the largest market share over the forecast period. CT scans are widely used first-line diagnostic tests for pleural diseases. Regionally, North America dominated the global pleural diseases market in 2024 owing to the growing geriatric population, improving healthcare infrastructure, and higher research initiatives in the region.
Competitor Insights:
Redax
Grena
Recent Developments
In June 2023, a global leader in biopharmaceuticals received FDA approval for their PD-1 inhibitor to treat malignant pleural mesothelioma. Clinical trials showed that the drug provided a significant survival benefit when added to standard chemotherapy for previously untreated mesothelioma. The approval represented an important new treatment option for this rare but aggressive cancer.
In July 2023, a mid-sized biotech company received both FDA and EMA approval for their IL-23 antagonist to treat pleural sarcoidosis. This was the first drug specifically approved to treat this inflammatory lung condition. In clinical trials, the IL-23 antagonist showed significant reductions in symptoms and objective markers of disease activity compared to placebo. The approval allowed patients with pleural sarcoidosis access to a targeted therapy for the first time.
Customize this study as per your requirement @ https://www.coherentmarketinsights.com/insight/request-customization/6038
Transform your Strategy with Exclusive Trending Reports:
The Global Ophthalmoscopes market is estimated to be valued at US$ 246.4 Mn in 2023 and is expected to exhibit a CAGR of 4.7% during the forecast period (2023-2030).
The global polyclonal antibody market size is expected to reach US$ 1,638.7 Mn by 2030, from US$ 1,096.9 Mn in 2023, exhibiting compound annual growth rate (CAGR) of 5.9% during the forecast period.
The Global Physician Office Diagnostic Market size was valued at US$ 104.47 billion in 2023 and is expected to reach US$ 258.21 billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 13.8% from 2023 to 2030.
Global preeclampsia diagnostics market is estimated to be valued at USD 2.10 Bn in 2024 and is expected to reach USD 4.12 Bn 2031, exhibiting a compound annual growth rate (CAGR) of 10.1% from 2024 to 2031.
About Us:
Coherent Market Insights leads into data and analytics, audience measurement,
consumer behaviors, and market trend analysis. From shorter dispatch to
in-depth insights, CMI has exceled in offering research, analytics, and
consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools
and custom-made research services, we empower businesses to move in the direction
of growth. We are multifunctional in our work scope and have 450+ seasoned
consultants, analysts, and researchers across 26+ industries spread out in 32+
countries.
Contact Us:
Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: + 12524771362
UK: +442039578553
AUS: +61-2-4786-0457
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
